Dashboard
Manage Tickers

ROIV


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

4-analysts-assess-roivant-sciences-what-you-need-to-know
4 Analysts Assess Roivant Sciences: What Y...
09/11/2024 14:00:41

b-of-a-securities-maintains-neutral-on-roivant-sciences-raises-price-target-to-125
B of A Securities Maintains Neutral on Roi...
09/11/2024 13:13:25

B of A Securities analyst Chi Fong maintains Roivant Sciences (NASDAQ:ROIV) with a Neutral and raises the price target from ...

hc-wainwright--co-reiterates-buy-on-roivant-sciences-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Roiv...
09/11/2024 10:32:30

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

roivant-sciences-unveils-new-vant-subsidiary-for-in-licensed-pulmonary-hypertension-drug-from-bayer
Roivant Sciences Unveils New 'Vant' Subsid...
09/10/2024 18:21:15

Roivant Sciences has licensed worldwide rights to develop and commercialize Bayer's mosliciguat for an upfront payment of $...

pulmovant-a-roivant-company-announced-the-presentation-of-data-from-the-proof-of-concept-phase-1b-atmos1-study-of-mosliciguat-an-inhaled-sgc-activator-with-targeted-delivery-to-the-lungs-and-once-daily-administration-in-pulmonary-hypertension-patients
Pulmovant, A Roivant Company, Announced Th...
09/10/2024 10:33:30

whats-going-in-with-vivek-ramaswamy-founded-roivant-sciences-stock-on-monday
What's Going In With Vivek Ramaswamy-Found...
09/09/2024 16:54:13

Immunovant reports promising Phase 2a trial results for batoclimab in treating Graves' Disease, showing a high response rat...

cantor-fitzgerald-reiterates-overweight-on-roivant-sciences
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 13:03:05

Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.

Core News & Articles
Roivant Says Immunovant Reported Results F...
09/09/2024 11:06:51

mmunovant also disclosed data from several proprietary market research studies that showed a consistent unmet need among ATD tr...

hc-wainwright--co-reiterates-buy-on-roivant-sciences-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Roiv...
08/19/2024 10:43:13

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

roivant-sciences-q1-2025-adj-eps-017-beats-026-estimate-sales-55132m-beat-31500m-estimate
Roivant Sciences Q1 2025 Adj. EPS $(0.17) ...
08/08/2024 11:08:03

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0....

piper-sandler-maintains-overweight-on-roivant-sciences-raises-price-target-to-22
Piper Sandler Maintains Overweight on Roiv...
07/10/2024 14:09:59

Piper Sandler analyst Allison Bratzel maintains Roivant Sciences (NASDAQ:ROIV) with a Overweight and raises the price target...

evaluating-roivant-sciences-insights-from-6-financial-analysts
Evaluating Roivant Sciences: Insights From...
06/18/2024 15:00:13

cantor-fitzgerald-reiterates-overweight-on-roivant-sciences
Cantor Fitzgerald Reiterates Overweight on...
06/18/2024 14:07:26

Cantor Fitzgerald analyst Louise Chen reiterates Roivant Sciences (NASDAQ:ROIV) with a Overweight.

the-analyst-verdict-roivant-sciences-in-the-eyes-of-6-experts
The Analyst Verdict: Roivant Sciences In T...
05/31/2024 14:00:16

hc-wainwright--co-reiterates-buy-on-roivant-sciences-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Roiv...
05/31/2024 10:38:57

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

roivant-sciences-q4-2024-gaap-eps-019-beats-032-estimate-sales-28930m-miss-32101m-estimate
Roivant Sciences Q4 2024 GAAP EPS $(0.19) ...
05/30/2024 11:02:13

Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0....

vivek-ramaswamy-breathes-new-life-into-beaten-down-buzzfeed-stock-whats-going-on
Vivek Ramaswamy Breathes New Life Into Bea...
05/22/2024 12:04:01

BuzzFeed shares surged after Vivek Ramaswamy acquired a 7.7% stake for $3.2 million.

roivant-and-kinevant-sciences-complete-enrollment-in-resolve-lung-phase-2-study-evaluating-namilumab-for-chronic-pulmonary-sarcoidosis
Roivant And Kinevant Sciences Complete Enr...
04/25/2024 12:08:24

critical-insights-from-roivant-sciences-analyst-ratings-what-you-need-to-know
Critical Insights From Roivant Sciences An...
04/22/2024 15:01:12

hc-wainwright--co-reiterates-buy-on-roivant-sciences-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on Roiv...
04/22/2024 10:34:04

HC Wainwright & Co. analyst Douglas Tsao reiterates Roivant Sciences (NASDAQ:ROIV) with a Buy and maintains $18 price ta...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION